Wall Street Analyst Upgrades to Watch

 TopRated
 
  TopRated
 
Follow  Message
 
 
TopRatedStocks uncovering top-rated companies. Providing quick insights and recommendations, they help investors discover high-potential stocks based on robust metrics.
 

•  01 Oct 2026
 

$EQIX Equinix picked up a fresh upgrade to Buy as the data center operator positions itself squarely inside the AI capital expenditure buildout cycle, with consolidation dynamics across the hyperscaler infrastructure space triggering the rating change. The stock is trading at $1,012.33, up a marginal 0.07% on volume of 384K against a 523K average, and the analyst target of $1,079.61 implies 6.56% near-term upside. Volume is running light relative to average, which tells you institutional positioning on this upgrade is still early and the market has not fully repriced the AI infrastructure thesis into the stock yet.

$REGN Regeneron Pharmaceuticals received the most substantive upgrade of the session, with Argus Research moving the biotech from Hold to Buy with a target of $852.03, representing 15.34% upside from the current price of $734.81. The stock is down 3.09% on the session, which is a notable divergence from the upgrade itself and creates a textbook entry dislocation where fundamental reassessment and near-term price weakness are pointing in opposite directions. Volume at 720K is running slightly above the 714K average, suggesting the selling pressure is not institutionally driven panic but rather routine repositioning. Argus upgrades carry weight in the biotech space and a Hold-to-Buy move from a research house with that credibility is not a Zacks momentum flag — it is a conviction call.

$CW Curtiss-Wright earned a Zacks upgrade to Buy with the most aggressive implied upside figure on this entire screen at 39.94%, with the analyst target sitting at $762.62 against a current price of $543.83. The defense and industrial technology compounder is trading up 0.16% on volume of 257K, which is running well below its 454K average, meaning the upgrade has not yet generated the kind of institutional response that typically follows a rating change of this magnitude. That volume gap is worth watching because when the broader defense sector catches a bid, names with this much implied upside to target tend to reprice quickly.

$BBY Best Buy is down 0.63% at $87.70 with volume tracking at 2.06M against a 3.97M average, and the upgrade carries a target of $94.83 implying 8.65% upside. The consumer electronics retailer is operating in a challenging discretionary spending environment, and the upgrade appears driven by valuation support rather than a fundamental acceleration thesis. Volume running at roughly half the average on the upgrade day is not a confidence signal.

$UTZ Utz Brands received a Zacks upgrade to Buy at $14.26, up 0.04% on 1.41M shares against a 1.89M average, with no disclosed price target in the source data. The branded snack company upgrade is a pure earnings estimate revision play and the near-term upside is difficult to size without a target anchor. It is the thinnest upgrade thesis on this list.

$TKNO Alpha Teknova moved to a Zacks Buy at $8.86, down 0.45% on 261K shares against a 236K average, with a target of $9.20 implying just 4.19% upside. Volume is marginally elevated relative to average but the implied return is the smallest on the screen and the life sciences reagent supplier operates in a niche with limited near-term catalyst visibility.

Bottom line: $REGN is the highest-conviction opportunity on this screen. A named analyst upgrade from Argus Research on a day when the stock is down 3.09% against a 15.34% target implies a genuine valuation disconnect rather than a momentum chase, and that combination of fundamental reassessment plus price weakness is the setup institutional desks build positions into, not away from. $CW is the second-ranked name on pure implied upside at nearly 40%, but the light volume response to the upgrade suggests the market needs a sector catalyst to unlock that return. $EQIX is the cleanest AI infrastructure play with the most durable structural thesis, but 6.56% upside to target does not qualify as a high-conviction near-term trade at current entry.

View all market intelligence